Long-term follow up of the CLL2007FMP trial evaluating fludarabine and cyclophosphamide in combination with either rituximab or alemtuzumab in previously untreated patients with chronic lymphocytic leukemia.
作者信息
Feugier Pierre, Aurran Thérèse, Mahé Béatrice, Letestu Remi, Nguyen-Khac Florence, Cazin Bruno, Tournilhac Olivier, Maisonneuve Hervé, Casasnovas Olivier, Delmer Alain, Leblond Véronique, Royer Bruno, Corront Bernadette, Chevret Sylvie, Delépine Roselyne, Vaudaux Sandrine, Van Den Neste Eric, Béné Marie-Christine, Cymbalista Florence, Ross-Weil Damien, Leprêtre Stéphane
机构信息
Service d'Hématologie, Centre Hospitalier Universitaire and INSERM 1256, Faculté de Médecine, Université de Lorraine, Vandoeuvrelès-Nancy, France
Service d'Hématologie, Institut Paoli-Calmettes, Marseille, France.
出版信息
Haematologica. 2018 Jul;103(7):e304-e306. doi: 10.3324/haematol.2017.183350. Epub 2018 Mar 15.
Abstract
摘要
相似文献
1
Long-term follow up of the CLL2007FMP trial evaluating fludarabine and cyclophosphamide in combination with either rituximab or alemtuzumab in previously untreated patients with chronic lymphocytic leukemia.CLL2007FMP试验的长期随访：评估氟达拉滨和环磷酰胺联合利妥昔单抗或阿仑单抗用于既往未治疗的慢性淋巴细胞白血病患者的疗效
Haematologica. 2018 Jul;103(7):e304-e306. doi: 10.3324/haematol.2017.183350. Epub 2018 Mar 15.
2
Cost-effectiveness of rituximab in addition to fludarabine and cyclophosphamide (R-FC) for the first-line treatment of chronic lymphocytic leukemia.利妥昔单抗联合氟达拉滨和环磷酰胺（R-FC）用于一线治疗慢性淋巴细胞白血病的成本效益
Leuk Lymphoma. 2016 May;57(5):1130-9. doi: 10.3109/10428194.2015.1070151. Epub 2015 Nov 20.
3
Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia.利妥昔单抗联合氟达拉滨和环磷酰胺相较于氟达拉滨和环磷酰胺单药治疗可延长先前治疗的慢性淋巴细胞白血病患者的无进展生存期。
J Clin Oncol. 2010 Apr 1;28(10):1756-65. doi: 10.1200/JCO.2009.26.4556. Epub 2010 Mar 1.
4
Low-dose fludarabine and cyclophosphamide combined with standard dose rituximab (LD-FCR) is an effective and safe regimen for elderly untreated patients with chronic lymphocytic leukemia: The Israeli CLL study group experience.低剂量氟达拉滨和环磷酰胺联合标准剂量利妥昔单抗（LD-FCR）治疗老年初治慢性淋巴细胞白血病患者安全有效：以色列 CLL 研究组经验。
Hematol Oncol. 2019 Apr;37(2):185-192. doi: 10.1002/hon.2580. Epub 2019 Mar 12.
5
First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial.一线苯达莫司汀和利妥昔单抗联合化疗与氟达拉滨、环磷酰胺和利妥昔单抗治疗晚期慢性淋巴细胞白血病（CLL10）患者：一项国际、开放标签、随机、III 期、非劣效性临床试验。
Lancet Oncol. 2016 Jul;17(7):928-942. doi: 10.1016/S1470-2045(16)30051-1. Epub 2016 May 20.
6
Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial.利妥昔单抗联合氟达拉滨和环磷酰胺治疗慢性淋巴细胞白血病患者的随机、开放标签、3 期临床试验。
Lancet. 2010 Oct 2;376(9747):1164-74. doi: 10.1016/S0140-6736(10)61381-5.
7
Rituximab, fludarabine, and cyclophosphamide versus fludarabine and cyclophosphamide for treatment of chronic lymphocytic leukemia: A systematic review with meta-analysis.利妥昔单抗、氟达拉滨和环磷酰胺与氟达拉滨和环磷酰胺治疗慢性淋巴细胞白血病的比较：系统评价与荟萃分析。
Crit Rev Oncol Hematol. 2015 Jun;94(3):261-9. doi: 10.1016/j.critrevonc.2015.02.013. Epub 2015 Mar 11.
8
Long-term results of chemoimmunotherapy with low-dose fludarabine, cyclophosphamide and high-dose rituximab as initial treatment for patients with chronic lymphocytic leukemia.低剂量氟达拉滨、环磷酰胺及高剂量利妥昔单抗化疗免疫疗法作为慢性淋巴细胞白血病患者初始治疗的长期结果
Blood. 2012 Mar 29;119(13):3184-5. doi: 10.1182/blood-2012-01-408047.
9
Efficacy and safety of front-line therapy with fludarabine-cyclophosphamide-rituximab regimen for chronic lymphocytic leukemia outside clinical trials: the Israeli CLL Study Group experience.氟达拉滨-环磷酰胺-利妥昔单抗方案一线治疗临床试验以外的慢性淋巴细胞白血病的疗效和安全性：以色列慢性淋巴细胞白血病研究组的经验
Haematologica. 2015 May;100(5):662-9. doi: 10.3324/haematol.2014.115808. Epub 2015 Feb 6.
10
Variations on the fludarabine, cyclophosphamide, and rituximab combination in chronic lymphocytic leukemia therapy: what have we learned?
J Clin Oncol. 2009 Feb 1;27(4):479-80. doi: 10.1200/JCO.2008.18.8698. Epub 2008 Dec 15.
引用本文的文献
1
Challenging the Value of Minimal Residual Disease in Predicting Outcome of Patients With Chronic Lymphocytic Leukemia.质疑微小残留病在预测慢性淋巴细胞白血病患者预后中的价值。
J Clin Oncol. 2023 Jul 20;41(21):3676-3678. doi: 10.1200/JCO.23.00619. Epub 2023 Jun 6.
本文引用的文献
1
The role of combined fludarabine, cyclophosphamide and rituximab chemoimmunotherapy in chronic lymphocytic leukemia: current evidence and controversies.氟达拉滨、环磷酰胺和利妥昔单抗联合化学免疫疗法在慢性淋巴细胞白血病中的作用：当前证据与争议
Ther Adv Hematol. 2017 Mar;8(3):99-105. doi: 10.1177/2040620716681749. Epub 2016 Dec 1.
2
Minimal residual disease is an independent predictor for 10-year survival in CLL.微小残留病是 CLL 患者 10 年生存的独立预测因子。
Blood. 2016 Dec 15;128(24):2770-2773. doi: 10.1182/blood-2016-05-714162. Epub 2016 Oct 3.
3
The HOVON68 CLL trial revisited: performance status and comorbidity affect survival in elderly patients with chronic lymphocytic leukemia.重新审视HOVON68慢性淋巴细胞白血病试验：体能状态和合并症对老年慢性淋巴细胞白血病患者生存的影响
Leuk Lymphoma. 2017 Mar;58(3):594-600. doi: 10.1080/10428194.2016.1213831. Epub 2016 Aug 2.
4
Eliminating minimal residual disease as a therapeutic end point: working toward cure for patients with CLL.将清除微小残留病作为治疗终点：致力于实现慢性淋巴细胞白血病患者的治愈
Blood. 2016 Jan 21;127(3):279-86. doi: 10.1182/blood-2015-08-634816. Epub 2015 Nov 17.
5
Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial.初治 CLL 患者采用 FCR 化免治疗后的长期缓解：CLL8 试验的更新结果。
Blood. 2016 Jan 14;127(2):208-15. doi: 10.1182/blood-2015-06-651125. Epub 2015 Oct 20.
6
Presence of multiple recurrent mutations confers poor trial outcome of relapsed/refractory CLL.存在多种复发突变可导致复发/难治性 CLL 的临床试验结局不佳。
Blood. 2015 Oct 29;126(18):2110-7. doi: 10.1182/blood-2015-05-647578. Epub 2015 Aug 27.
7
Frontline low-dose alemtuzumab with fludarabine and cyclophosphamide prolongs progression-free survival in high-risk CLL.一线低剂量阿仑单抗联合氟达拉滨和环磷酰胺可延长高危 CLL 患者的无进展生存期。
Blood. 2014 May 22;123(21):3255-62. doi: 10.1182/blood-2014-01-547737. Epub 2014 Apr 15.
8
Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia.综合突变和细胞遗传学分析确定慢性淋巴细胞白血病的新预后亚组。
Blood. 2013 Feb 21;121(8):1403-12. doi: 10.1182/blood-2012-09-458265. Epub 2012 Dec 13.
9
Excess mortality after treatment with fludarabine and cyclophosphamide in combination with alemtuzumab in previously untreated patients with chronic lymphocytic leukemia in a randomized phase 3 trial.在一项随机 3 期临床试验中，在未经治疗的慢性淋巴细胞白血病患者中，用氟达拉滨和环磷酰胺联合阿仑单抗治疗后的超额死亡率。
Blood. 2012 May 31;119(22):5104-10. doi: 10.1182/blood-2011-07-365437. Epub 2012 Feb 14.
10
An open-label, pilot study of fludarabine, cyclophosphamide, and alemtuzumab in relapsed/refractory patients with B-cell chronic lymphocytic leukemia.氟达拉滨、环磷酰胺和阿仑单抗治疗复发/难治性 B 细胞慢性淋巴细胞白血病患者的开放性、先导研究。
Blood. 2011 Oct 13;118(15):4079-85. doi: 10.1182/blood-2011-05-351833. Epub 2011 Jul 19.
Zotero 插件